Multiple Sclerosis: all 3,524 studies

Page 28 of 36. Open to participants first (668), then studies with results posted, then the rest; newest registration first within each.

• Longitudinal Analysis And Sample Collection To Evaluate PML Risk Host Markers for PML Risk Host Markers for PML RiskCompletedNCT02440126
• Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)WithdrawnNCT02428218Phase 3
• VR-treadmill Combined Intervention for Enhancing Mobility and Cognitive Function in Patients With Multiple SclerosisCompletedNCT02427997Not applicable
• A Trial for Evaluating Both Safety and Preliminary Efficacy of a Single Infusion of Stimulated Autologous CD4+T Cells in Patients With Relapsing- Remitting Multiple SclerosisTerminatedNCT02427776Phase 1/2
• Rouxbe Pilot for MSCompletedNCT02424825Not applicable
• Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple SclerosisCompletedNCT02424396Phase 2
• Oral Guanabenz for Multiple SclerosisTerminatedNCT02423083Phase 1
• A Task-oriented Circuit Training in Multiple SclerosisCompletedNCT02421744Not applicable
• Robot-assisted Gait Training on Mobility in Severely Disabled Multiple Sclerosis PatientsCompletedNCT02421731Not applicable
• Comparison of Rebif Compared to Tecifdera on Six-month Outcomes in Patients With Relapsing-remitting MSWithdrawnNCT02419638
• Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective PotentialCompletedNCT02419378Phase 4
• Role of Neuromuscular Junction Function in Motor Fatigue in Multiple SclerosisCompletedNCT02418897
• A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMSTerminatedNCT02418325Phase 1/2
• Calorie Restriction in Multiple Sclerosis PatientsCompletedNCT02411838Not applicable
• Assistive Device Training in Multiple SclerosisCompletedNCT02408718Not applicable
• Analysis of a Biomarker Signature in Patients With Multiple Sclerosis (MS) Treated With Gilenya (FTY720)Status unknownNCT02408380
• Intensity Depended Impacts on Cognitive Functions in Persons With Multiple Sclerosis - a Pilot StudyStatus unknownNCT02408367
• MEsenchymal StEm Cells for Multiple SclerosisTerminatedNCT02403947Phase 1/2
• Rotating Frame Relaxation Imaging in Patients With Multiple SclerosisCompletedNCT02403570
• An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a RelapseCompletedNCT02398461Phase 1
• Characterizing Upper Extremity Function in Individuals With Multiple SclerosisCompletedNCT02398149
• Observational Study of Rebismart®2.0 + MSdialog™ in Subjects With Remitting Multiple Sclerosis (ADHERQOL)TerminatedNCT02394782
• An Online Self-Guided Meditation Course for Individuals With Multiple SclerosisCompletedNCT02391298Not applicable
• Validation of Brief Computerized Cognitive Assessment in Multiple Sclerosis (BCCAMS)CompletedNCT02391064Not applicable
• Falls Prevention and Balance Rehabilitation in Multiple SclerosisCompletedNCT02390830Not applicable
• Transcranial Doppler in Multiple SclerosisCompletedNCT02389426Not applicable
• Impact of Multiple Sclerosis From the Viewpoint of the Patients and Their CaregiversCompletedNCT02388334
• Observational Study to Assess the Correlation of EDSS With Quality of Life in MS Participants Treated With NatalizumabCompletedNCT02386566
• Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients - A Three Year ExtensionCompletedNCT02383550
• Real-Life Outcomes of Multiple Sclerosis Treatment With RebifCompletedNCT02377323Not applicable
• Endpoint Calibration for a Phase 2 Study of Lisinopril in Multiple SclerosisStatus unknownNCT02369926Phase 2
• Multicenter Validation of The Evergreen Myometric Strength Test for Lower Extremities (EMST-LE) in Multiple Sclerosis: Protocol for Strength Testing and Reliability CharacteristicsCompletedNCT02369224
• A Database Study to Estimate the Risk of Multiple Sclerosis Following Vaccination With Arepanrix™ in Manitoba, CanadaCompletedNCT02367222
• Phototherapy in Persons With Multiple SclerosisStatus unknownNCT02365259Phase 1
• Immune- and miRNA-response to Recombinant Interferon Beta in Healthy Volunteers and Patients With Relapsing Remitting Multiple SclerosisStatus unknownNCT02364986Phase 1
• A Telemedicine Mindfulness-based Intervention for People With Multiple Sclerosis and Their CaregiversCompletedNCT02364505Not applicable
• DTI in Children With Multiple SclerosisStatus unknownNCT02361697Not applicable
• Physical Capacity and Rehabilitation of Patients With Multiple SclerosisStatus unknownNCT02352194
• Responsiveness and Minimal Clinical Important Difference of the Multiple Sclerosis Questionnaire for PhysiotherapistsCompletedNCT02346279
• Mindfulness-based Stress Reduction for Multiple SclerosisCompletedNCT02340754Not applicable
• Psychometric Properties Mobility Measures MSCompletedNCT02339688Not applicable
• Psychometric Properties Upper Limb Function Measures Multiple SclerosisCompletedNCT02339675Not applicable
• PROFILE - Evaluation of QoL and PRO Outcomes in Patients Taking FingolimodCompletedNCT02335892
• Spinal Direct Current Stimulation Effects on Pain in Multiple SclerosisStatus unknownNCT02331654Not applicable
• Mechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple SclerosisCompletedNCT02330965
• Multi-Center Study Safety of Adipose Derived Mesenchymal Stem Cells for the Treatment of Multiple SclerosisTerminatedNCT02326935Phase 1
• Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to GilenyaStatus unknownNCT02325440Phase 4
• Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve)TerminatedNCT02323269
• Computerized Cognition Testing and Cognitive Motor Interference in MSCompletedNCT02318576Not applicable
• A Trial to Investigate the Effectiveness of Testosterone Treatment in Men With Multiple SclerosisWithdrawnNCT02317263Phase 2
• Fall Risk Reduction in Multiple Sclerosis (FIRMS)Status unknownNCT02314585Not applicable
• A Long-term Follow-up Study Of Multiple Sclerosis Patients Who Participated In Genzyme-sponsored Studies of GZ402668CompletedNCT02313285
• Comparative Oral Bioavailability Study of MT-1303CompletedNCT02310048Phase 1
• Evaluate the Effect of Switching From Daily Injections of 20mg Glatiramer Acetate (GA) to 40mg GA Three Times a Week in Subjects With Relapsing-remitting Multiple SclerosisCompletedNCT02308670
• Centralized Reading Assessment of Chronic CerebroSpinal Venous Insufficiency (CCSVI) in Patients With Multiple Sclerosis and Other Neurological DiseasesCompletedNCT02308579
• Domperidone in Secondary Progressive Multiple Sclerosis (SPMS)CompletedNCT02308137Phase 2
• Comparison of Brain Atrophy Rates, Cognition, and Patient-Reported Outcomes in MS Patients Using Long-term Fingolimod and Glatiramer AcetateCompletedNCT02307877
• Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839TerminatedNCT02306811Phase 2
• Imaging of Intracerebral Inflammation in MSCompletedNCT02305264Not applicable
• Aggressive Onset Multiple Sclerosis: A Practical Definition and Study of Its Clinical CourseCompletedNCT02301572
• Step it Up: An Exercise and Behaviour Change Programme for People With Multiple SclerosisCompletedNCT02301442Not applicable
• Speed of Processing Training to Improve Cognition in Multiple SclerosisCompletedNCT02301260Not applicable
• Treating New Learning and Memory Deficits in Progressive Multiple Sclerosis (MS)CompletedNCT02301247Not applicable
• Physical Activity in Multiple Sclerosis (MS): A Novel Approach to Study OutcomesCompletedNCT02297932Not applicable
• Mass Balance Study of MT-1303CompletedNCT02293967Phase 1
• Robot-assisted Gait Training in Patients With Multiple Sclerosis: Efficacy and Comparison With Traditional MethodsStatus unknownNCT02291107Not applicable
• Efficacy Study of "Imaginative Distention", a Self Managed Tool to Cope With Fatigue,Insomnia and Stress in pw Insomnia and pw MSCompletedNCT02290990Not applicable
• Study of Social Cognition by Morphological and Functional Imaging in Multiple Sclerosis PatientsCompletedNCT02290587Not applicable
• Wii FIT Balance Board to Recording Balance Parameters in Multiple Sclerosis SubjectsCompletedNCT02287948
• Integrative Group-based Cognitive Rehabilitation Efficacy in Multiple SclerosisCompletedNCT02287454Not applicable
• Testing the Effects of Methylphenidate on Multiple SclerosisCompletedNCT02286557Phase 2
• Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 BCompletedNCT02283671Phase 1
• The Effect of Dietary Salt Intake on Immune Function in Patients With Multiple SclerosisCompletedNCT02282878Not applicable
• A First-in-human, Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple SclerosisCompletedNCT02282826Phase 1
• Efficacy Study of Andrographis Paniculata Purified Standardized Extract (ApE) in Patients With Multiple Sclerosis (MS)CompletedNCT02280876Phase 1/2
• Disease Control in RRMS Transferring Treatment From Natalizumab to FingolimodCompletedNCT02277964
• Study to Investigate the Immune Response and Safety of Prophylactic Vaccines in Patients Treated for Multiple SclerosisCompletedNCT02275741
• Cognitive Motor Interference Rehabilitation in Persons With Multiple SclerosisCompletedNCT02274935Not applicable
• Efficacy, Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MSStatus unknownNCT02273635Phase 1/2
• Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy VolunteersCompletedNCT02269930Phase 1
• Improving Cognitive Aptitudes With tDCS in Patients With Multiple SclerosisTerminatedNCT02266121Not applicable
• Exercise Intensity and Immune Function in Multiple SclerosisStatus unknownNCT02264704Not applicable
• Exercise & Brain Health in MSCompletedNCT02263339Not applicable
• Efficacy of Dalfampridine on Upper Extremity Function in Patients With MSStatus unknownNCT02259361Phase 4
• Robot-assisted Training of the Upper Limb in Persons With Multiple Sclerosis: an Randomized Controlled TrialCompletedNCT02257606Not applicable
• A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis PatientsCompletedNCT02253264Phase 1
• BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With BetaferonCompletedNCT02247310
• Safety and Efficacy of Intravenous Autologous Mesenchymal Stem Cells for MS: a Phase 2 Proof of Concept StudyCompletedNCT02239393Phase 2
• Aerobic Exercise and Flu-like Symptoms Following Interferon Beta 1a Injections in Patients With Multiple Sclerosis?CompletedNCT02236624Not applicable
• Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon TherapyWithdrawnNCT02234869Phase 4
• Plegridy Observational ProgramCompletedNCT02230969
• Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple SclerosisCompletedNCT02228213Phase 2
• Trekking Poles to Aid Multiple Sclerosis Gait ImpairmentCompletedNCT02227524Not applicable
• Assessing Induction of Type II (M2) Monocytes/Macrophages in Patients Receiving Gilenya.CompletedNCT02225977
• Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple SclerosisTerminatedNCT02222948Phase 2
• Effect of MD1003 in Spinal Progressive Multiple SclerosisStatus unknownNCT02220933Phase 3
• Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple SclerosisStatus unknownNCT02220244Phase 3
• Restoring Glutathione Synthesis With Tecfidera: An in Vivo H-MRS Single-Arm Study at 7T in Patients With RR MSTerminatedNCT02218879
• Safety, Tolerability and Efficacy of Monthly Long-acting IM Injection of 80 or 40 mg GA Depot in Subjects With RRMSCompletedNCT02212886Phase 1/2
• Balance and Falls in Multiple SclerosisCompletedNCT02209467Not applicable

← Multiple Sclerosis overview